A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Systemic Pharmacokinetics of Icenticaftor in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants
Latest Information Update: 16 Nov 2022
Price :
$35 *
At a glance
- Drugs Icenticaftor (Primary)
- Indications Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 14 Nov 2022 Status changed from recruiting to completed.
- 25 Jul 2022 Planned End Date changed from 30 Aug 2022 to 31 Oct 2022.
- 25 Jul 2022 Planned primary completion date changed from 30 Aug 2022 to 31 Oct 2022.